Neurocrine Biosciences
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| neurology | ×1.21 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| preclinical | ×1.40 | 3 |
Strategy profile
Based on 15 disclosed transactions, Neurocrine Biosciences concentrates its licensing activity in Neurology, RareDisease. Neurocrine Biosciences pays a 1.32x premium over market median, with the strongest premiums in Neurology (1.21x). Their most common deal structure is Collaboration, with an average disclosed value of $2.6B. Most recent activity: 2026.
Premium by therapeutic area
How Neurocrine Biosciences pays relative to peer medians in each TA
Pipeline coverage & gaps
Neurocrine Biosciences has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 8 | $126M | $2.8B |
| License | 5 | $124M | $1.9B |
| Acquisition | 1 | $2.9B | $2.9B |
| Co Development | 1 | $175M | $4.4B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Vykat XR | Soleno Therapeutics | hyperphagia | unknown | $2.9B | $2.9B |
| 2023 | Anti-Tau antibody transport vehicle | Voyager Therapeutics | Alzheimer's Disease, Tauopathies | preclinical | $115M | $1.7B |
| 2023 | GBA1 program | Voyager Therapeutics | — | preclinical | $175M | $4.4B |
| 2023 | GBA1 gene-therapy program | Voyager Therapeutics | Gaucher disease | preclinical | $175M | $4.4B |
| 2023 | GBA1 gene therapy and rare CNS programs | Voyager Therapeutics, Inc. | parkinson's disease | preclinical | $175M | $4.1B |
| 2022 | parkinsons | Voyager Therapeutics | parkinsons | preclinical | $165M | $1.7B |
| 2021 | M4, M1 and M1/M4 dual muscarinic agonist programs | Sosei Heptares | schizophrenia | discovery | $100M | $2.7B |
| 2021 | GPCR-targeted CNS programs | Heptares Therapeutics Limited | cns | discovery | $100M | $2.7B |
| 2021 | Muscarinic receptor agonist portfolio (including HTL0018318) | Sosei Group / Sosei Heptares | schizophrenia and other neuropsychiatric disorders | preclinical | $100M | $2.7B |
| 2021 | NBI-1117567 | Nxera Pharma | Alzheimer's cognition, schizophrenia, dementia and other neuropsychiatric disorders | preclinical | — | $2.6B |
| 2020 | Seven early-to-mid-stage psychiatry programs | Takeda Pharmaceutical Company Limited | cns | phase_2 | $120M | $2.0B |
| 2020 | TAK-831 (luvadaxistat) | Takeda Pharmaceutical | schizophrenia | phase_2 | $120M | $2.0B |
| 2019 | XEN901 and related sodium-channel programs | Xenon Pharmaceuticals | epilepsy | preclinical | $50M | $1.8B |
| 2019 | Multi-program collaboration (including VY-FXN01) | Voyager Therapeutics | Friedreich's ataxia | preclinical | $165M | $1.9B |
| 2019 | VY-AADC | Voyager Therapeutics, Inc. | parkinson's disease | phase_2 | $115M | $1.8B |
How this is computed
For each Neurocrine Biosciences deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 1.319, clamped to [0.7, 1.5].